NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES |
OMB APPROVAL |
OMB Number: |
3235-0080 |
Expires: |
March 31, 2018 |
Estimated average burden |
hours per response: |
1.7 |
|
|
SECURITIES AND EXCHANGE COMMISSION |
Washington, D.C. 20549 |
FORM 25 |
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
Commission File Number |
001-31326 |
|
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
|
Address: |
950 Winter Street |
|
Waltham |
MASSACHUSETTS |
02451 |
Telephone number: |
| 781-577-5300 |
|
(Address, including zip code, and telephone number, including area code, of Issuer's
principal executive offices)
|
Common stock |
(Description of class of securities)
|
|
Please place an X in the box to designate the rule provision relied upon to strike
the class of securities from listing and registration:
|
|
Pursuant to the requirements fo the Securities Exchange Act of 1934,
Nasdaq Stock Market LLC
certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing the Form 25 and has caused this notification to be
signed on its behalf by the undersigned duly authorized person.
|
2024-03-20 |
By |
Aravind Menon |
|
Hearings Advisor |
Date |
|
Name |
Title |
|
1 |
Form 25 and attached Notice will be considered compliance with the provisions of
17 CFR 240.19d-1 as applicable. See General Instructions.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
|
Delisting Determination, The Nasdaq Stock Market, LLC, March 21, 2024,
Eloxx Pharmaceuticals, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of Eloxx Pharmaceuticals, Inc., effective
at the opening of the trading session on April 1, 2024.
On April 11, 2023, Nasdaq Listing Qualifications staff (Staff) notified
Eloxx Pharmaceuticals, Inc. (Company) that it determined to delist the
Company based on its noncompliance with Rule 5550(b)(2). On April 18,
2023, the Company exercised its right to appeal the Staff determination
to the Listing Qualifications Hearings Panel (Panel) pursuant to Rule
5815. A Panel hearing was held on May 18, 2023. On June 2, 2023, the
Panel issued a decision to continue listing the Company securities
provided certain conditions were met. On October 12, 2023, the Panel
issued a decision to delist the shares of the Company due to the Company
failure to regain compliance with Rule 5550(b)(2). On October 26, 2023,
the Company exercised its right to appeal the Panel decision to the
Nasdaq Listing and Hearing Review Council (Council) pursuant to Rule
5820(a). On December 21, 2023, the Council issued a decision that
affirmed the Panel decision to delist the Company securities. On
February 7, 2024, the Company was provided notice that the Nasdaq Board
of Directors declined to call the Council decision for review pursuant
to Rule 5825(a). The Staff determination to delist the Company units
and rights became final on February 7, 2024.